Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 3/20 | 0.41 |
| ▸ | HPGD | P15428 | 3/20 | 0.41 |
| ▸ | POLB | P06746 | 3/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | GLA | P06280 | 2/20 | 0.40 |
| ▸ | ACHE | P22303 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | SLCO1B3 | Q9NPD5 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1820328 | 0.87 | LMNA (0.43) | CYP3A4HPGDPOLBLMNATP53 | |
| SCHEMBL17736228 | 0.85 | CA12 (0.42) | CYP3A4HPGDPOLBLMNATP53 | |
| SCHEMBL15725731 | 0.85 | CYP3A4 (0.45) | CYP3A4HPGDPOLBLMNATP53 | |
| SCHEMBL1822757 | 0.81 | MAPK1 (0.44) | CYP3A4HPGDPOLBLMNATP53 | |
| SCHEMBL23118246 | 0.77 | POLB (0.47) | CYP3A4HPGDPOLBALDH1A1MEN1 | |
| SCHEMBL28284531 | 0.75 | CYP3A4 (0.50) | CYP3A4HPGDPOLBLMNANPSR1 | |
| SCHEMBL1495316 | 0.75 | CA12 (0.41) | CYP3A4HPGDPOLBLMNANPSR1 | |
| SCHEMBL1901154 | 0.74 | TSHR (0.48) | CYP3A4HPGDLMNATP53NPSR1 | |
| SCHEMBL6828207 | 0.74 | CYP3A4 (0.41) | CYP3A4HPGDPOLBALDH1A1SMN1; SMN2 | |
| SCHEMBL4395785 | 0.73 | KDM4E (0.46) | CYP3A4HPGDPOLBLMNATP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170360785-A1 | PYRIMIDINE FGFR4 INHIBITORS | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2017-12-21 | — | — | US | disclosed |
| US-9730931-B2 | Pyrimidine FGFR4 inhibitors | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2017-08-15 | — | — | US | disclosed |
| US-20170007601-A1 | PYRIMIDINE FGFR4 INHIBITORS | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2017-01-12 | — | — | US | disclosed |
| US-9434697-B2 | Pyrimidine FGFR4 inhibitors | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2016-09-06 | — | — | US | disclosed |
| US-20160130237-A1 | PYRIMIDINE FGFR4 INHIBITORS | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2016-05-12 | — | — | US | disclosed |
| WO-2015057963-A1 | FGFR4 INHIBITORS | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2015-04-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170360785-A1 | PYRIMIDINE FGFR4 INHIBITORS | FGFR4, FGFR1, FGFR3 | CYP3A4 929/4885HPGD 3348/4885POLB 731/4885 |
| US-20160130237-A1 | PYRIMIDINE FGFR4 INHIBITORS | FGFR4, FGFR1, FGFR3 | CYP3A4 929/4885HPGD 3348/4885POLB 731/4885 |
| US-20170007601-A1 | PYRIMIDINE FGFR4 INHIBITORS | FGFR4, FGFR1, FGFR3 | CYP3A4 929/4885HPGD 3348/4885POLB 731/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.